BIOMAT Database Logo BIOMAT Database Logo

Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma. 2017

Vasudha Abbhi, and Lovneet Saini, and Srishti Mishra, and Gautam Sethi, and Alan Prem Kumar, and Poonam Piplani
University Institute of Pharmaceutical Sciences, UGC-Center of Advanced Study (UGC-CAS), Panjab University, Chandigarh 160014, India. Electronic address: manuabbhi88@gmail.com.

Rho kinase inhibitors (ROCK II) play a key role in glaucoma management attributed to their IOP lowering ability and neuroprotective effects. In the present study, a series of novel benzimidazole derivatives (9a-m) has been synthesized and evaluated for their IOP lowering, Rho kinase inhibitory and antioxidant properties. The synthesized compounds were found to be lipophilic and showed a significant IOP lowering effect both in the treated and the contralateral eye comparable to the reference standard fasudil. The nitrophenyl piperazine substituted compound 9j exhibited significant IOP lowering (51.56%) and an inhibition of 57.25 and 77.92% towards ROCK II enzyme at a concentration of 0.5 and 1 mM respectively. It possessed a considerable free radical scavenging activity exhibiting an IC50 value of 95.49 µg/mL in DPPH assay. The molecular docking studies of compound 9j indicated the binding of the compound at the active site of recombinant human ROCK II which makes it a promising antiglaucoma agent.

UI MeSH Term Description Entries
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D005901 Glaucoma An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed) Glaucomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive
D001562 Benzimidazoles Compounds with a BENZENE fused to IMIDAZOLES.
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Vasudha Abbhi, and Lovneet Saini, and Srishti Mishra, and Gautam Sethi, and Alan Prem Kumar, and Poonam Piplani
Benzimidazole- and benzoxazole-based inhibitors of Rho kinase.
December 2008, Bioorganic & medicinal chemistry letters,
Vasudha Abbhi, and Lovneet Saini, and Srishti Mishra, and Gautam Sethi, and Alan Prem Kumar, and Poonam Piplani
Rho kinase inhibitors for treatment of glaucoma.
January 2011, Expert review of ophthalmology,
Vasudha Abbhi, and Lovneet Saini, and Srishti Mishra, and Gautam Sethi, and Alan Prem Kumar, and Poonam Piplani
Rho kinase inhibitors for glaucoma treatment - Review.
January 2015, Arquivos brasileiros de oftalmologia,
Vasudha Abbhi, and Lovneet Saini, and Srishti Mishra, and Gautam Sethi, and Alan Prem Kumar, and Poonam Piplani
Investigational Rho Kinase Inhibitors for the Treatment of Glaucoma.
January 2021, Journal of experimental pharmacology,
Vasudha Abbhi, and Lovneet Saini, and Srishti Mishra, and Gautam Sethi, and Alan Prem Kumar, and Poonam Piplani
Rho Kinase (ROCK) Inhibitors for the Treatment of Glaucoma.
January 2024, Current drug targets,
Vasudha Abbhi, and Lovneet Saini, and Srishti Mishra, and Gautam Sethi, and Alan Prem Kumar, and Poonam Piplani
Design and synthesis of Rho kinase inhibitors (II).
January 2007, Bioorganic & medicinal chemistry,
Vasudha Abbhi, and Lovneet Saini, and Srishti Mishra, and Gautam Sethi, and Alan Prem Kumar, and Poonam Piplani
Design and synthesis of Rho kinase inhibitors (I).
May 2004, Bioorganic & medicinal chemistry,
Vasudha Abbhi, and Lovneet Saini, and Srishti Mishra, and Gautam Sethi, and Alan Prem Kumar, and Poonam Piplani
Design and synthesis of rho kinase inhibitors (III).
January 2007, Bioorganic & medicinal chemistry,
Vasudha Abbhi, and Lovneet Saini, and Srishti Mishra, and Gautam Sethi, and Alan Prem Kumar, and Poonam Piplani
An emerging treatment option for glaucoma: Rho kinase inhibitors.
January 2014, Clinical ophthalmology (Auckland, N.Z.),
Vasudha Abbhi, and Lovneet Saini, and Srishti Mishra, and Gautam Sethi, and Alan Prem Kumar, and Poonam Piplani
Design and synthesis of potent and selective azaindole-based Rho kinase (ROCK) inhibitors.
December 2008, ChemMedChem,
Copied contents to your clipboard!